A detailed history of Vanguard Group Inc transactions in Kronos Bio, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,922,809 shares of KRON stock, worth $1.87 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,922,809
Previous 1,948,595 1.32%
Holding current value
$1.87 Million
Previous $2.53 Million 5.88%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.73 - $1.38 $18,823 - $35,584
-25,786 Reduced 1.32%
1,922,809 $2.38 Million
Q1 2024

May 10, 2024

BUY
$1.02 - $1.3 $252,876 - $322,293
247,918 Added 14.58%
1,948,595 $2.53 Million
Q4 2023

Feb 14, 2024

BUY
$0.75 - $1.49 $9,234 - $18,344
12,312 Added 0.73%
1,700,677 $2.13 Million
Q3 2023

Nov 14, 2023

BUY
$1.23 - $2.25 $109,470 - $200,250
89,000 Added 5.56%
1,688,365 $2.19 Million
Q2 2023

Aug 14, 2023

BUY
$1.24 - $1.92 $119,720 - $185,374
96,549 Added 6.42%
1,599,365 $2.75 Million
Q1 2023

May 15, 2023

SELL
$1.34 - $2.62 $2,822 - $5,517
-2,106 Reduced 0.14%
1,502,816 $2.19 Million
Q4 2022

Feb 10, 2023

BUY
$1.44 - $3.44 $3,366 - $8,042
2,338 Added 0.16%
1,504,922 $2.44 Million
Q3 2022

Nov 14, 2022

SELL
$3.35 - $5.55 $1.03 Million - $1.7 Million
-307,087 Reduced 16.97%
1,502,584 $5.03 Million
Q2 2022

Aug 12, 2022

SELL
$3.12 - $7.52 $2.47 Million - $5.95 Million
-791,820 Reduced 30.44%
1,809,671 $6.59 Million
Q1 2022

May 13, 2022

SELL
$6.26 - $14.42 $4.95 Million - $11.4 Million
-790,825 Reduced 23.31%
2,601,491 $18.8 Million
Q4 2021

Feb 14, 2022

BUY
$11.35 - $21.18 $665,053 - $1.24 Million
58,595 Added 1.76%
3,392,316 $46.1 Million
Q3 2021

Nov 12, 2021

BUY
$18.17 - $24.7 $6.79 Million - $9.23 Million
373,518 Added 12.62%
3,333,721 $69.9 Million
Q2 2021

Aug 13, 2021

BUY
$20.08 - $29.02 $59.4 Million - $85.9 Million
2,960,203 New
2,960,203 $70.9 Million

Others Institutions Holding KRON

About Kronos Bio, Inc.


  • Ticker KRON
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,769,100
  • Market Cap $55.1M
  • Description
  • Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...
More about KRON
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.